Wednesday, 16 June 2021
Home »
Health
,
Health news
,
IFTTT
,
NYT
» CureVac’s mRNA vaccine reaches an efficacy level of just 47 percent in a clinical trial.
CureVac’s mRNA vaccine reaches an efficacy level of just 47 percent in a clinical trial.
By BY CARL ZIMMER from NYT Health https://ift.tt/2S4aRhB
0 comments:
Post a Comment